Skip to main content
. 2016 Dec 23;89(4):431–440.

Figure 2.

Figure 2

CBX7i with doxorubicin decreases cell viability. a. U118MG cells treated with CBX7i in the presence (grey) or absence (black) of 100 nM doxorubicin total protein measured by sulforhodamine B 515 nm absorbance (n = 3) b. U118MG cells treated with doxorubicin in the presence (grey) or absence (black) of 250 µM CBX7i bulk protein measured by sulforhodamine B 515 nm absorbance (n = 3) c. U118MG cells were treated with CBX7i in the presence (grey) or absence (black) of 100 nM doxorubicin and counted (n = 3) d. U118MG cells in a 96 well plate were treated CBX7i in the presence (grey) or absence (black) of 50 nM doxorubicin for five days and counted (n = 3) Data in a-d represented by mean ± SEM, p-values calculated with student’s t-test: (*) < 0.05, p (**) < 0.01, p (***) < 0.001.